Results 241 to 250 of about 18,682 (303)

Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma

European Journal of Haematology, Volume 116, Issue 6, Page 797-805, June 2026.
ABSTRACT Objectives CAR‐T cell therapies such as lisocabtagene maraleucel (liso‐cel) have transformed the treatment of patients with second line primary refractory or early relapsed ≤ 12 months (R/R) large B‐cell lymphoma (LBCL). The objective of this study was to assess the cost‐effectiveness of liso‐cel compared to standard of care (SOC) to treat R/R
Catherine Thieblemont, Florian Colrat, Rahma Sellami, Marine Sivignon, Adrien Petel, Sébastien Branchoux, Gérard de Pouvourville   +6 more
wiley   +1 more source

Human induced pluripotent stem cell-derived neural stem/progenitor cell therapy for spinal cord injury: preclinical advances and translational perspectives. [PDF]

Stem Cells Transl Med
Ogaki R, Nagoshi N, Okano H, Nakamura M.
europepmc   +1 more source

Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High‐Risk Hematological Malignancies

European Journal of Haematology, Volume 116, Issue 6, Page 907-914, June 2026.
ABSTRACT Introduction Allogeneic stem cell transplantation (allo‐SCT) and donor lymphocyte infusions (DLI) can elicit a graft‐versus‐leukemia (GvL) effect in pediatric patients with hematological malignancies. We report our single‐center experience with prophylactic DLI in high‐risk pediatric patients with leukemia or lymphoma, focusing on feasibility,
Denise Epple, Katja Gall, Luisa Paschke, Hans‐Jochem Kolb, Angela Wawer, Hans Knabe, Irene von Luettichau, Julia Hauer, Uwe Thiel   +8 more
wiley   +1 more source

Relapse of Acute Myeloid Leukemia With Concomitant Systemic Mastocytosis Five Years Post Allogenic Hematopoietic Stem Cell Transplantation. [PDF]

Case Rep Hematol
Vardanyan S, Gjelberg HK, Helgeland L, Tsykunova G, Forthun RB, Reikvam H.   +5 more
europepmc   +1 more source

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy

European Journal of Haematology, Volume 116, Issue 6, Page 771-784, June 2026.
ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

The lost chord: Microchimerism [PDF]

, 1996
Demetris, AJ, Murase, N, Rao, AS, Starzl, TE, Thomson, AW, Trucco, M   +5 more
core  

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real‐World Evidence in a Rapidly Evolving Therapeutic Landscape

European Journal of Haematology, Volume 116, Issue 6, Page 928-936, June 2026.
ABSTRACT Modern therapies have clearly marked the history of multiple myeloma (MM), leading to undisputed advantages in terms of sustained responses and prolonged survival, while progressively improving patients' quality of life. Nonetheless, disease recurrence and resistance to available therapies underscore the importance of identifying additional ...
K. Mancuso, S. Masci, M. Talarico, A. Vitale, S. Barbato, V. Solli, M. Puppi, I. Rizzello, L. Pantani, P. Tacchetti, M. Iezza, R. Restuccia, I. Sacchetti, E. Manzato, S. Ghibellini, S. Armuzzi, B. Taurisano, M. Cavo, E. Zamagni   +18 more
wiley   +1 more source

Generation of primordial germ cell-like cells by two germ plasm components, <i>dnd1</i> and <i>nanos3</i>, in medaka (<i>Oryzias latipes</i>). [PDF]

iScience
Nishimura T, Fujimoto T.
europepmc   +1 more source

Functional mouse hepatocytes derived from interspecies chimeric livers effectively mitigate chronic liver fibrosis. [PDF]

Stem Cell Reports
Huang C, Jiang H, Dong J, Jiang L, Li J, Xu J, Cui T, Wang L, Li X, Feng G, Zhang Y, Li T, Li W, Zhou Q.   +13 more
europepmc   +1 more source